Nitrogen‐containing bisphosphonates inhibit the mevalonate pathway and prevent post‐translational prenylation of GTP‐binding proteins, including Ras
SP Luckman, DE Hughes, FP Coxon… - Journal of bone and …, 1998 - academic.oup.com
Bisphosphonates are currently the most important class of antiresorptive drugs used for the
treatment of metabolic bone diseases. Although the molecular targets of bisphosphonates …
treatment of metabolic bone diseases. Although the molecular targets of bisphosphonates …
Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates
…, K Thompson, FP Coxon, SP Luckman… - … of Pharmacology and …, 2001 - ASPET
It has long been known that small changes to the structure of the R 2 side chain of nitrogen-containing
bisphosphonates can dramatically affect their potency for inhibiting bone …
bisphosphonates can dramatically affect their potency for inhibiting bone …
The pharmacology of bisphosphonates and new insights into their mechanisms of action
…, MJ Rogers, JC Frith, SP Luckman… - Journal of Bone and …, 1999 - Wiley Online Library
Bisphosphonates are chemically stable analogs of inorganic pyrophosphate, which are
resistant to breakdown by enzymatic hydrolysis. The biological effects of bisphosphonates on …
resistant to breakdown by enzymatic hydrolysis. The biological effects of bisphosphonates on …
Heterocycle‐containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: Evidence from structure‐activity relationships …
SP Luckman, FP Coxon, FH Ebetino… - Journal of Bone and …, 1998 - academic.oup.com
Recent evidence suggests that bisphosphonates (BPs) may inhibit bone resorption by
mechanisms that lead to osteoclast apoptosis. We have previously shown that BPs also reduce …
mechanisms that lead to osteoclast apoptosis. We have previously shown that BPs also reduce …
Partial characterization of cell-type X collagen interactions
SP Luckman, E Rees, APL Kwan - Biochemical Journal, 2003 - portlandpress.com
Type X collagen is a short-chain non-fibrillar collagen that is deposited exclusively at sites
of new bone formation. Although this collagen has been implicated in chondrocyte …
of new bone formation. Although this collagen has been implicated in chondrocyte …
[HTML][HTML] Matrix metalloproteinase-3 in myasthenia gravis compared to other neurological disorders and healthy controls
SP Luckman, NE Gilhus, F Romi - Autoimmune Diseases, 2011 - hindawi.com
MMP-3 is capable of degrading a variety of proteins, including agrin, which plays a critical
role in neuromuscular signaling by controlling acetylcholine receptor clustering. High MMP-3 …
role in neuromuscular signaling by controlling acetylcholine receptor clustering. High MMP-3 …
Nitrogen‐containing biphosphonates inhibit the mevalonate pathway and prevent post‐translational prenylation of GTP‐binding proteins, including Ras
SP Luckman, DE Hughes, FP Coxon… - Journal of Bone and …, 2005 - academic.oup.com
Bisphosphonates are currently the most important class of antiresorptive drugs used for the
treatment of metabolic bone diseases. Although the molecular targets of bisphosphonates …
treatment of metabolic bone diseases. Although the molecular targets of bisphosphonates …
Serum matrix metalloproteinase-3 levels are elevated in myasthenia gravis
FR Romi, NE Gilhus, SP Luckman - Journal of neuroimmunology, 2008 - Elsevier
MMP-3 is capable of degrading a variety of proteins, including agrin, which plays a critical
role in neuromuscular signalling by controlling acetylcholine receptor clustering. The …
role in neuromuscular signalling by controlling acetylcholine receptor clustering. The …
JBMR anniversary classic. Nitrogen-containing biophosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins …
SP Luckman, DE Hughes, FP Coxon… - Journal of bone …, 2005 - pubmed.ncbi.nlm.nih.gov
… Steven P Luckman, David E Hughes, Fraser P Coxon, Graham G Russell, Michael J Rogers …
Myasthenia gravis sera have no effect on cardiomyocytes in vitro
G Helgeland, SP Luckman, FR Romi… - Journal of …, 2008 - Elsevier
Myasthenia gravis (MG) is an autoimmune disorder primarily caused by circulating autoantibodies
targeting the nicotinic acetylcholine receptor. Several studies have suggested a link …
targeting the nicotinic acetylcholine receptor. Several studies have suggested a link …